

SERIAL NO.
09/081,522

APPLICANT
Brooks, et al.

FILING DATE
05/19/98

GROUP
1644

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

[illegible]

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

09/081522

FILING DATE


05/19/98

GROUP

1644

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
M	A01	5,766,591	6/16/98	Brooks et al.			
	A02						
	A03						
	A04						
	A05						
	A06						
	A07						
	A08						
	A09						



FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B01							
	B02							
	B03							
	B04							
	B05							

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

M	C01	Gutheil, et al., "Targeted Antiangiogenic Therapy for Cancer Using vitaxin: A Humanized Monoclonal Antibody to the Integrin $\alpha_v\beta_3$ ", Clin.Cancer Research 6: 3056-3061 (2000).
	C02	
	C03	

EXAMINER

Pittman GMBE 4/12/04

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Use several sheets if necessary)

09/08/522
Brooks et al.

FILING DATE
05/19/98

GROUP
1644

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
Ne	A01	5,578,704	11/26/96	Kim			
	A02	5,652,109	7/29/97	Kim			
	A03	5,652,110	7/29/97	Kim			
	A04	5,677,181	10/14/97	Parish			
	A05	5,874,081	02/23/99	Parish			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	B01	WO 94/10331	5/11/94				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	C01	Adams et al., "Increased Affinity Leads to Improved Selective Tumor Delivery of Single-Chain Fv Antibodies," <u>Cancer Research</u> 58: 485-490 (1998).
	C02	Carmeliet, "Integrin indecision," <u>Nature Medicine</u> 8: 14-16 (2002).
	C03	Cheresh, "Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor," <u>Proc. Natl. Acad. Sci USA</u> 84: 6471-6475 (1987).
	C04	Cheresh et al., "Integrin-mediated death: An explanation of the integrin-knockout phenotype?" <u>Nature Medicine</u> 8: 193-194 (2002).
	C05	Posey et al., "Pilot Trial of Vitaxin, A Humanized Anti-Vitronectin Receptor (anti $\alpha_v\beta_3$) Antibody in Patients with Metastatic Cancer," <u>Cancer Biotherapy & Radiopharmaceuticals</u> 16: 125-132 (2001).
	C06	Rader et al., "Phage display approach for rapid antibody humanization: Designed combinatorial V gene libraries," <u>Proc. Natl. Acad. Sci. USA</u> 95: 8910-8915 (1998).
	C07	Reynolds et al., "Enhanced pathological angiogenesis in mice lacking β_3 integrin or β_3 and β_5 integrins," <u>Nature Medicine</u> 8: 27-34 (2002).
	C08	Schier et al., "Isolation of High-affinity Monomeric Human Anti-c-erbB-2 Single chain Fv Using affinity-driven Selection," <u>J. Mol. Biol.</u> 255: 28-43 (1996).
Plu	C09	Schier et al., "Isolation of Picomolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding Site," <u>J. Mol. Biol.</u> 263: 551-567 (1996).

EXAMINER

Thompson

DATE CONSIDERED

4/12/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.